Literature DB >> 19273247

The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor.

Andrea Ecker1, Olivia Simma, Andrea Hoelbl, Lukas Kenner, Hartmut Beug, Richard Moriggl, Veronika Sexl.   

Abstract

Stat transcription factors have been implicated in tumorigenesis in mice and men. Stat3 and Stat5 are considered powerful proto-oncogenes, whereas Stat1 has been demonstrated to suppress tumor formation. We demonstrate here for the first time that a constitutive active version of Stat3alpha (Stat3alphaC) may also suppress transformation. Mouse embryonic fibroblasts (MEFs) deficient for p53 can be transformed with either c-myc or with rasV12 alone. Interestingly, transformation by c-myc is efficiently suppressed by co-expression of Stat3alphaC, but Stat3alphaC does not interfere with transformation by the rasV12-oncogene. In contrast, transplantation of bone marrow cells expressing Stat3alphaC induces the formation of a highly aggressive T cell leukemia in mice. The leukemic cells invaded multiple organs including lung, heart, salivary glands, liver and kidney. Interestingly, transplanted mice developed a similar leukemia when the bone marrow cells were transduced with Stat3beta, which is also constitutively active when expressed at significant levels. Our experiments demonstrate that Stat3 has both - tumor suppressing and tumor promoting properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273247     DOI: 10.2741/3425

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  26 in total

Review 1.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

Review 2.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

3.  Multiple pathways regulate Cten in colorectal cancer without a Tensin switch.

Authors:  Hannah Thorpe; Maham Akhlaq; Darryl Jackson; Saleh Al Ghamdi; Sarah Storr; Stewart Martin; Mohammad Ilyas
Journal:  Int J Exp Pathol       Date:  2016-01-19       Impact factor: 1.925

4.  Signal transducer and activator of transcription-3 and breast cancer prognosis.

Authors:  Takahiro Sato; Lynn Moretti Neilson; Amy R Peck; Chengbao Liu; Thai H Tran; Agnes Witkiewicz; Terry Hyslop; Marja T Nevalainen; Guido Sauter; Hallgeir Rui
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

Review 5.  Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).

Authors:  Andrew Dunbar; Abbas Nazir; Ross Levine
Journal:  Curr Protoc Pharmacol       Date:  2017-06-22

6.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

Review 7.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

8.  STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain.

Authors:  Olga A Timofeeva; Nadya I Tarasova; Xueping Zhang; Sergey Chasovskikh; Amrita K Cheema; Honghe Wang; Milton L Brown; Anatoly Dritschilo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-03       Impact factor: 11.205

9.  STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models.

Authors:  Francesca Marino; Valeria Orecchia; Gabriella Regis; Monica Musteanu; Beatrice Tassone; Cristina Jon; Marco Forni; Enzo Calautti; Roberto Chiarle; Robert Eferl; Valeria Poli
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 10.  EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.

Authors:  Hui-Wen Lo
Journal:  Curr Mol Pharmacol       Date:  2010-01       Impact factor: 3.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.